Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback